Savant Capital LLC Invests $65,000 in Nuvation Bio Inc. $NUVB

Savant Capital LLC acquired a new position in Nuvation Bio Inc. (NYSE:NUVB) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 33,522 shares of the company’s stock, valued at approximately $65,000.

Other large investors have also bought and sold shares of the company. Atria Investments Inc acquired a new position in Nuvation Bio during the 2nd quarter worth about $42,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Nuvation Bio during the second quarter worth about $131,000. Envestnet Asset Management Inc. acquired a new position in shares of Nuvation Bio in the second quarter worth approximately $92,000. Brighton Jones LLC bought a new stake in Nuvation Bio in the second quarter valued at approximately $120,000. Finally, CWM LLC increased its position in Nuvation Bio by 296.4% during the 2nd quarter. CWM LLC now owns 37,963 shares of the company’s stock valued at $74,000 after purchasing an additional 28,387 shares during the period. 61.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Gary Hattersley sold 100,000 shares of Nuvation Bio stock in a transaction on Monday, October 27th. The shares were sold at an average price of $5.02, for a total value of $502,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dongfang Liu sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $5.10, for a total transaction of $76,500.00. Following the sale, the insider owned 18,000 shares of the company’s stock, valued at $91,800. This trade represents a 45.45% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 160,000 shares of company stock worth $797,800. 29.93% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NUVB. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Wednesday, October 8th. Citizens Jmp lifted their target price on shares of Nuvation Bio from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research note on Thursday. Jefferies Financial Group began coverage on shares of Nuvation Bio in a research report on Tuesday, September 30th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Nuvation Bio in a report on Friday, September 19th. Finally, Royal Bank Of Canada boosted their price objective on Nuvation Bio from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.50.

Nuvation Bio Stock Performance

Shares of Nuvation Bio stock opened at $7.01 on Friday. The business has a 50-day simple moving average of $4.26 and a 200 day simple moving average of $3.05. Nuvation Bio Inc. has a one year low of $1.54 and a one year high of $7.50. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.48 and a quick ratio of 8.39. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of -10.95 and a beta of 1.50.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The business had revenue of $13.12 million for the quarter, compared to analyst estimates of $7.48 million. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%. On average, research analysts anticipate that Nuvation Bio Inc. will post -0.36 earnings per share for the current fiscal year.

Nuvation Bio Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.